Elizabeth Barrett - Jan 31, 2024 Form 4 Insider Report for UroGen Pharma Ltd. (URGN)

Role
Chief Executive Officer
Signature
/s/ Jason D. Smith, Attorney-in-Fact
Stock symbol
URGN
Transactions as of
Jan 31, 2024
Transactions value $
$0
Form type
4
Date filed
2/2/2024, 07:04 PM
Previous filing
Jun 15, 2023
Next filing
Jun 7, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction URGN Restricted Stock Units Award $0 +87.6K $0.00 87.6K Jan 31, 2024 Ordinary Shares 87.6K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.
F2 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2025, January 31, 2026 and January 31, 2027.